Human Genome Sciences seeks approval for Zalbin
Rocky Mount Telegram - Business (Free subscription) | 25/11/2009
NEW YORK — Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of it...
Human Genome Sciences, Inc.
Your search relates to more than one category
+Vote!
+Vote!
Human Genome Sciences seeks approval for Zalbin
Miami Herald (Free subscription) | 25/11/2009
Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
+Vote!
Human Genome Sciences seeks approval for Zalbin
San Fransisco Chronicle (Free subscription) | 25/11/2009
Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin. The Rockville, Md., company did not say when it expected a response to its biologics license application, which was submitted to the Food and Drug... Human Genome Sciences - Hepatitis C - Biology - Genetics - Eukaryotic
+Vote!
Human Genome Sciences seeks approval for Zalbin
San Diego Union (Free subscription) | 25/11/2009
Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
+Vote!
Human Genome Sciences seeks approval for Zalbin
Seattle Post-Intelligencer (Free subscription) | 25/11/2009
NEW YORK -- Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
+Vote!
Human Genome Sciences seeks approval for Zalbin
Seattle Times (Free subscription) | 25/11/2009
Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
+Vote!
Human Genome Sciences Begins Tumor Treatment Trial
SeekingAlpha.com (Free subscription) | 25/11/2009
Zacks.com submits: Recently, Human Genome Sciences, Inc. ( HGSI ) and Aegera Therapeutics announced the initiation of dosing in a phase I clinical trial to evaluate the safety and tolerability of its lead inhibitor-of-apoptosis protein (IAP), HGS1029, as monotherapy in patients with advanced lymphoid tumors. An additional phase I clinical trial of the compound is being conducted to evaluate...
+Vote!
Human Genome Sciences submitted application for new drug Zalbin
The Washington Business Journal (Free subscription) | 25/11/2009
Human Genome Sciences Inc. announced today it’s submitted its second application so far this year to federal regulators to sell a drug on the market, this most recent being for its hepatitis C treatment called Zalbin. (HGSI)
3Vote!
Human Genome Sciences Submits Biologics License Application to FDA for ZALBIN™
Business Wire (Free subscription) | 25/11/2009
ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon...
+Vote!
Human Genome Sciences And Aegera Therapeutics Announce Initiation Of Clinical Trial Of Lead IAP Inhibitor HGS1029 In Advanced Lymphoid Tumors
Medical News Today (Free subscription) | 24/11/2009
Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.
+Vote!
Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors
Business Wire (Free subscription) | 23/11/2009
ROCKVILLE, Md. & MONTREAL--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors. “We are pleased to initiate this first human...